Summit Therapeutics SMMT Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $537.67M+257% | $150.78M+154% | $59.47M+14.4% | $52M-39.1% | ||
| $556.75M+825% | $60.21M+106% | $29.26M+9.4% | $26.74M+13.3% | ||
| $1.09B+384% | $226M-62.9% | $609.65M+599% | $87.21M-20.0% | ||
| $14.84M+11.0% | $13.37M+19.5% | $11.18M— | —— | ||
| -$1.08B-388% | -$221.32M+64.0% | -$614.93M-681% | -$78.78M+11.1% | ||
| -$1.44-350% | -$0.32+78.5% | -$1.49-263% | -$0.41+39.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Summit Therapeutics profitable?
- Summit Therapeutics is not currently profitable: it reported a net loss of $1.2B over the trailing twelve months, a -271685.0% net margin.
- What is Summit Therapeutics's earnings per share?
- Summit Therapeutics's diluted EPS over the trailing twelve months is $-1.59.
- Where does Summit Therapeutics's income statement data come from?
- Every line is extracted from Summit Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.